Is Tirzepatide the New Game Changer in Type 2 Diabetes?

<b>Background:</b> Tirzepatide (TZP) is a once-weekly glucagon-like peptide 1 (GLP-1) and glucose-dependent-insulinotropic-polypeptide (GIP) receptor co-agonist approved for T2D. TZP provides promising evidence in improving glucose control and weight loss in T2D and obesity across precli...

Full description

Bibliographic Details
Published in:Endocrines
Main Authors: Giuseppe Lisco, Olga Eugenia Disoteo, Vincenzo De Geronimo, Anna De Tullio, Vito Angelo Giagulli, Edoardo Guastamacchia, Giovanni De Pergola, Emilio Jirillo, Vincenzo Triggiani
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Subjects:
tirzepatide
type 2 diabetes
glycemic control
weight loss
cardiovascular outcomes
renal outcomes
Online Access:https://www.mdpi.com/2673-396X/5/1/5

Internet

https://www.mdpi.com/2673-396X/5/1/5

Similar Items